Medtech
Stocks – How a company’s IP portfolio Creates Market Leaders
Stocks
Mentioned: (Nasdaq: $AEMD), (NASDAQ: $IINN), (NASDAQ: $AMIX), (NYSE: $PHG)
September
4, 2025- Investorideas.com, a
go-to investing platform covering biotech and medtech stocks releases an
industry snapshot looking at innovation and the importance of IP in medtech,,
featuring Aethlon Medical,
Inc. (Nasdaq:AEMD), a
medical therapeutic company focused on developing products to treat cancer and
life-threatening infectious diseases.
Medical
Device Online reported in July, “The
global medical device market is estimated to be currently about $680 billion
and is projected to grow to over a trillion dollars within 10 years at a
compound annual growth rate of 6%. As the medical device industry continues to
expand, intellectual property (IP) considerations — especially those concerning
patents — are critical for medical device innovators and manufacturers. For
companies, developing IP is essential for securing funding, negotiating
partnerships, and positioning themselves as leaders in the industry. For
investors, a company’s IP portfolio signifies its ability to maintain market
exclusivity and defend against competition.”
Aethlon Medical,
Inc.
(Nasdaq:AEMD) with
its unique medical device, Hemopurifier®, is building an impressive list of
patents issued and pending. It just announced that US Patent No. 12,409,260
("the “260 Patent") directed to treatment of Long COVID will issue on
September 9, 2025, and Unitary European Patent 4136453 (the “453 Patent)”
directed to the treatment of COVID-19-associated coagulopathy (“CAC”) was issued
July 9, 2025.
Paid News Dissemination of behalf of AEMD.
Read this news
featuring AEMD in full at: https://www.investorideas.com/CO/AEMD/news/2025/09041medtech-stocks-ip-portfolio-market-leaders.asp
From the news:
The
260 Patent is intended to protect the use of the Hemopurifier® in the United
States to treat patients that have a reduced COVID-19 viral load but exhibit
Long COVID symptoms for more than 12 weeks post infection. The 260 Patent
additionally protects the treatment of patients experiencing Long COVID
symptoms by the removal of circulating COVID-19 spike protein.
The
453 Patent is intended to protect the use of the Hemopurifier® for the
treatment of patients that lack circulating COVID-19 viral particles but
exhibit COVID-19-associated CAC.
The
260 Patent was granted an additional 385 days of patent term due to patent term
adjustment and will expire in 2042. The 453 Patent will expire in 2041.
"We
believe securing these patents expands and strengthens our intellectual
property portfolio in areas of significant unmet medical need,” said James
Frakes, CEO and CFO of Aethlon. “While the Hemopurifier® remains in the
research and development stage relating to Long COVID, these protections
position us well as we continue advancing potential future applications. Our
goal is to build a strong foundation of innovation that could one day translate
into meaningful treatment options for patients."
The
Aethlon Hemopurifier® is an investigational medical device designed to remove
enveloped viruses, fragments of viruses, and tumor-derived extracellular
vesicles (EVs) from circulation. It is used extra-corporeally with a blood pump
and combines plasma separation, size exclusion, and affinity binding using a
plant lectin resin that targets mannose-rich surfaces found on EVs and viral
proteins. EVs released by solid tumors are believed to play a role in
metastasis and the resistance to immunotherapies and chemotherapy. Removal of
enveloped viruses, fragments of viruses, and extracellular vesicles has been
demonstrated in both in vitro studies and in human patients.
The
Hemopurifier® holds a US Food and Drug Breakthrough Device Designation for:
The
treatment of individuals with advanced or metastatic cancer unresponsive to or
intolerant of standard-of-care therapy; and the treatment of life-threatening
viruses not addressed with approved therapies.
In
addition to this patent news, Aethlon has the following patents issued and
multiple patents pending in the
US and Internationally:
International
Patents issued
14
patents covering exosomes and microvesicular particle removal
•
Patent protection extending to 2031 in Germany, France, Great Britain and Spain
•
Patent protection extending to 2027 in Canada, Switzerland, Italy, Netherlands,
Sweden, Hong Kong, Demark and Ireland
•
4 patents covering removal of Covid-19 viral particles and associated exosomes.
•
Patent protection extending to 2041 in Unitary Patent member states, Switzerland,
Great Britain and Spain
Issued
Patents In United States:
•
4 patents issued covering extracorporeal removal of microvesicular particles,
patent protection until 2029
Inspira™
Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), a
pioneer in innovative life-support and diagnostic technologies recently announced it
received US Patent approval for low flow rates extracorporeal oxygenation
system and methods of use. This patent represents the core technology of the
ART500 device, a key asset in the Company’s strategy to penetrate the $20
billion estimated market for advanced respiratory support. This innovation has
16 claims found to be novel.
From the news:
The
patent provides further protection for the underlying core technology of
Inspira’s ART500 system, which is designed to provide extracorporeal
oxygenation at low flow rates while maintaining patient safety and treatment
efficiency. This capability targets a large, underserved patient population
that requires respiratory support but may not be sick enough for traditional,
high-flow ECMO systems, significantly expanding the potential market for
Inspira's technology. This approval strengthens Inspira’s intellectual property
portfolio and reinforces the Company’s technological leadership in the field of
advanced extracorporeal life support.
Dagi
Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: "This
patent has profound business implications for Inspira and for our ability to
dominate a market with a potential size of $20 billion. We are creating a new
therapeutic category for conscious, spontaneously breathing patients.
Protecting our intellectual property is a critical pillar of our growth
strategy, and this patent approval provides us with a distinct competitive
advantage. While our ART100 system is already generating commercial momentum,
this move fortifies our future and gives us the clear runway needed to
translate our technological leadership into long-term value for our
shareholders, and a new standard of care for patients worldwide."
The
newly received patent provides protection at least until the year 2043,
covering key claims related to the ART500’s functionality, design, and clinical
applications. Inspira is pursuing additional patents in major jurisdictions
worldwide to expand its intellectual property coverage.
In
late August, Autonomix Medical, Inc. (NASDAQ:AMIX), a
medical device company dedicated to advancing precision nerve-targeted
treatments announced that
European Patent Office (EPO) has granted Patent No. 3,697,298 (the ‘298
patent), titled, “Medical Device with Circuitry for Capturing and Processing
Physiological Signals.” The newly issued ‘298 patent relates to use of its proprietary
technology to collect and process sensing data for real-time physiological
monitoring with broad application use that includes coronary artery/vagal nerve
mapping, arterial/renal mapping, bladder/lower urinary tract applications,
robotic prosthetics and implants, and central nervous system monitoring for
neurotherapy.
Earlier
this year, Royal Philips (NYSE:PHG) announced that in
2024 it was the leading applicant in the field of medical technology at the
European Patent Office (EPO), filing 594 Medtech patent applications. This
achievement underscores the company's ongoing dedication to transforming
healthcare delivery by integrating informatics and AI to improve workflows,
enhance the quality of care, and lower costs of care per patient.
From the news:
AI-enabled
cardiovascular ultrasound platform
The
innovations by Philips, which can boast 134 years of innovation history with
its research and development programs around the globe, improved the health and
well-being of nearly 2 billion people in 2024, keeping it on track towards its
target of 2.5 billion lives improved in 2030.
Roy
Jakobs, CEO of Royal Philips said: "For more than 130 years, Philips has
been at the forefront of innovations improving people’s lives. The 2024
European patent rankings show how we continue to innovate in the hospital and
the home – helping to deliver better care for more people. To continue driving
greater impact, we have shifted our innovation closer to customers. We want to
help healthcare professionals improve patient care and empower people
everywhere to take care of their health and well-being.”
As
informatics and AI increasingly create value for healthcare, both at the
hospital as well as at home, approximately half of the company’s R&D
investments are focused on these technologies.
Some of the informatics and AI-powered
innovations that Philips launched in 2024 include:
·
The new Azurion image-guided therapy system
with advanced informatics to enhance minimally invasive diagnosis and treatment
of stroke and other neurovascular patients.
·
FDA-cleared AI tools integrated into the
EPIQ CVx and Affiniti CVx ultrasound system to advance cardiovascular imaging
and increase automation and productivity, reinforcing Philips’ #1 global
position in cardiovascular ultrasound.
·
The new Philips Spectral CT 7500 RT,
enabling personalized radiation therapy planning to deliver better care to more
cancer patients.
·
FDA approval for the LumiGuide Navigation
Wire, which uses fiber optic technology to reduce radiation for both patients and
physicians during minimally invasive surgery.
In
total, Philips contributed 1,231 European patent applications across various
domains, the most of any Dutch company and continuing the company’s legacy as
one of the top applicants since the EPO started publishing the rankings in
2004.
Based
on market projections from leading analysts, the medical device market is set
for significant expansion, fueled by technological advancements and growing
healthcare needs.
Aethlon Medical,
Inc.
(Nasdaq:AEMD) is
advancing its Hemopurifier® blood purification device globally with a growing
patent portfolio to strengthen its long-term competitive advantage in the sector.
Research biotech and medical device/ tech stocks at Investorideas.com
https://www.investorideas.com/BIS/
About Investorideas.com - Big
Investing Ideas
Investorideas.com is the go-to platform for big
investing ideas. From breaking stock news to top-rated investing podcasts, we
cover it all.
Disclaimer/Disclosure: This news
article featuring AEMD is a paid for news release on Investorideas.com. AEMD is
an annual featured
showcase stock at Investorideas.com This is not investment opinion. Our site does not make recommendations for purchases or
sale of stocks, services or products.
This is not investment opinion: Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investing involves risk and possible losses. More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact
Investorideas.com
800-665-0411
